Clinical Trial Detail

NCT ID NCT03164772
Title Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Ludwig Institute for Cancer Research
Indications

lung non-small cell carcinoma

Therapies

BI 1361849 + Durvalumab + Tremelimumab

Age Groups: adult senior

Additional content available in CKB BOOST